Why this trial matters : First oral SERD to succeed in Phase III in early breast cancer Signals a potential new adjuvant standard of care Advances endocrine therapy beyond legacy agents Johnson & Johnson Tecvayli + Darzalex Faspro Shows Unprecedented Phase III Success in Relapsed/Refractory Multiple Myeloma The Phase III MajesTEC-3 trial demonstrated that the combination of Tecvayli (teclistamab) plus Darzalex Faspro (daratumumab SC) significantly improved progression-free survival and overall survival versus standard regimens in patients with relapsed/refractory multiple myeloma as early as second-line, with an ~83% reduction in disease progression or death at almost three years follow-up
Additionally, novel biologics, including synthetic peptides, may eventually be used to enhance and speed up musculoskeletal recovery
Carnitine levels and the ketogenic diet
Your consultation is the best way to discover whether we are the right fit for your healing journey
If those appear, the reaction is something more serious than the copper uglies and you should stop the product immediately and consult a dermatologist
Novo Nordisks CagriSema Shows Strong Weight-Loss Results But Trails Eli Lillys Tirzepatide in Latest Clinical Data Feb 26, 2026 A New Chapter in the Global Anti-Obesity Drug Race The competition to develop next-generation obesity therapies intensified following the release of new Phase III clinical data for CagriSema, an investigational drug from Novo Nordisk
